ArticleJournal of psychiatric research2020
Predicting relapse after alcohol use disorder treatment in a high-risk cohort: The roles of anhedonia and smoking.
Article in Journal of psychiatric research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Functional magnetic response imaging predictors of alcohol use disorder treatment outcome: a systematic review.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Pooled it
- A Membrane-Centric Plasma Lipidomic Signature of Response to Long-Acting Naltrexone in Alcohol Use Disorder.Addiction biology · 2026Trial
- Intermittent theta burst to the left dorsolateral prefrontal cortex promoted decreased alcohol consumption and improved outcomes in those with alcohol use disorder: A randomized, double-blind, placebo-controlled clinical trial.Drug and alcohol dependence · 2025Trial
- Modeling Concurrent Hedonic Disruption During Excessive Drinking and Abstinence-Related Negative Affect in a Novel Selectively Bred Mouse Line: The Crossed High Alcohol Preferring X High Drinking in the Dark (cHAPxHDID) Mice.Alcohol, clinical & experimental research · 2026Article
- The OPRM1 A118G G Allele Is Associated With Poorer Auditory-Verbal Learning and Memory, Executive Functions, and Working Memory in Veterans Undergoing Residential Treatment for Alcohol Use Disorder.Alcohol, clinical & experimental research · 2026Article
- Barriers and Access to Care for Firefighters With Posttraumatic Stress Disorder Seeking Ketamine-Assisted Therapy: A Qualitative Study.Journal of occupational and environmental medicine · 2026Article
- Attitudes of older adults toward active euthanasia in advanced Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2026Article
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- Predictors and Trajectories of Negative and Positive Interpersonal Dynamics in Remission From Alcohol Use Disorder.Alcohol, clinical & experimental research · 2026Article
- Cross-Species evidence for hippocampal CACNA1C as a therapeutic target for alcohol use disorder.Translational psychiatry · 2026Article
- CeA-projecting VTA neurons contribute to alcohol withdrawal-induced anxiety-like behavior in male and female rats.Alcohol (Fayetteville, N.Y.) · 2026Article
- Celebrating each success: proportion of remission as a measure of recovery from polysubstance use disorder proportion of remission; a recovery measure.Harm reduction journal · 2026Article
- Alcohol Use in a Tribal Rural Population of India: Prevalence, Social Determinants, and Impact of a Community-Based Health System-Integrated Intervention.Addiction & health · 2026Article
- The impact and experience of a culturally adapted brief intervention for harmful alcohol use in an emergency care setting (PPKAY: Punguza Pombe Kwa Afya Yako): A case series.medRxiv : the preprint server for health sciences · 2025Article
- Treatment patterns and healthcare resource use among veterans initiating medication for incident moderate-to-severe alcohol use disorder.The American journal on addictions · 2025Article
- Gut microbiota and alcohol use disorder: a new frontier in treatment and recovery.BJPsych bulletin · 2025Review
- Thiamine Deficiency and Neuroinflammation Are Important Contributors to Alcohol Use Disorder.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Review
- A Customized Neural Transcranial Magnetic Stimulation Target for Functional Disability Among Veterans With Co-Occurring Alcohol Use Disorder and Mild Traumatic Brain Injury: Protocol for a Pilot Randomized Controlled Trial.JMIR research protocols · 2025Article
- Impact of psychiatric pharmacist-led ambulatory alcohol withdrawal management.The mental health clinician · 2025Article
- Digital interventions for supporting alcohol abstinence in aftercare - a systematic review.Internet interventions · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
On average, two-thirds of individuals treated for alcohol use disorder (AUD) relapse within six months. There is a critical need to identify modifiable risk factors associated with relapse that can be addressed during AUD treatment. Candidate factors include mood disorders and cigarette smoking, which frequently co-occur with AUD. We predicted that co-occurrence of mood disorders, cigarette smoking, and other modifiable conditions will predict relapse within six months of AUD treatment. Ninety-five Veterans, 23-91 years old, completed assessments of multiple characteristics including demographic information, co-occurring psychiatric disorders, and medical conditions during residential treatment for AUD. Participants' alcohol consumption was monitored over six months after participation. Logistic regression was used to determine if, mood disorders, cigarette smoking status, alcohol consumption, educational level, and comorbid general medical conditions are associated with relapse after AUD treatment. Sixty-nine percent of Veterans (n = 66) relapsed within six months of study while 31% remained abstinent (n = 29). While education, comorbid general medical conditions, and mood disorder diagnoses were not predictors of relapse, Veterans with greater symptoms of anhedonia, active smokers, and fewer days of abstinence prior to treatment showed significantly greater odds for relapse within six months. Anhedonia and cigarette smoking are modifiable risk factors, and effective treatment of underlying anhedonic symptoms and implementation of smoking cessation concurrent with AUD-focused interventions may decrease risk of relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.